on Moderna, Inc. (NASDAQ:MRNA)
Moderna's mNEXSPIKE Shows Strong Immune Response Against COVID-19 LP.8.1 Variant
Moderna, Inc. has revealed promising preliminary data for its mNEXSPIKE vaccine, targeting the COVID-19 LP.8.1 variant. The 2025-2026 formula demonstrated a significant boost in neutralizing antibodies, with over a 16-fold increase among individuals aged 12-64 with high-risk conditions and adults over 65. These results also follow similar findings from Spikevax, which showed an 8-fold antibody increase in comparable age groups.
The vaccine's safety profile aligns with previous data, supporting the FDA’s approval for its use in specified age groups. The study underpins the vaccine’s efficacy against prevalent COVID-19 strains. Moderna continues to monitor safety and effectiveness in this ongoing Phase 4 trial.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Moderna, Inc. news